Anna P. Solovyova

Anna P. Solovyova

Auto-generated profile, based on publicly available information

Anna P. Solovyova

Scientific Centre for Expert Evaluation of Medicinal Products

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2018 in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
Verified
Journal Article
Open access
ASA. P. Solovyova
A. P. Solovyova
DGD. V. Goryachev
D. V. Goryachev
VAV. V. Arkhipov
V. V. Arkhipov

31 March 2025 in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
Verified
Journal Article
Open access
PDF file
ASA. P. Solovyova
A. P. Solovyova
ISI. M. Surmilo
I. M. Surmilo
   Introduction. Dementia is a heterogeneous class of diseases, the individual subtypes of which are distinguished based on etiological factors, the nature of disorders, the course of dementia, as well as laboratory instruments and neuroimaging. Among the diseases whose leading clinical syndrome is dementia, Alzheimer's disease (AD), vascular dementia, dementia with Lewy bodies, Pick's disease, Creutzfeldt-Jakob disease, Huntington's chorea, Parkinson's disease, the effects of traumatic brain injury, brain tumor, dementia with substance abuse and other diseases. Currently, there is no treatment that could significantly slow down or stop the effects of AD on the brain, and the search continues for ways to improve the treatment of AD. The search for effective and safety drugs for the treatment of AD is an extremely important task, which determines the urgency of developing new drugs for its treatment. Proper program planning and clinical trials are necessary to obtain reliable data on the efficacy and safety of drugs. Currently, there are no documents in the Russian Federation (RF) and the Eurasian Economic Union (EEU) regulating the conduct of clinical trials of drugs used to treat AD.   Objective. The aim of this study was to analyze regulatory approaches to planning clinical research programs for drugs used for AD treatment abroad and to assess the possibility of extrapolation to RF clinical practice in the development of drugs for AD treatment.   Discussion. The strategy for conducting clinical trials of drugs and the requirements for data volume and quality regarding efficacy and safety are presented. This article was prepared on the basis of recommendations approved by the RF for the planning and development of medicines, guidelines for the examination of drugs, EU regulatory requirements, and documents from the International Council for the Harmonization of Technical Requirements for the Registration of Medicines for Medical Use (ICH).   Conclusion. An analysis of the Guidelines of the European Medicines Agency (EMA), which regulate the basic principles and key aspects of conducting preclinical and clinical trials on drugs for the treatment of AD, was carried out. The provisions of the EMA guidelines can be used as a basis for developing drug research programmes for treating diseases. It is advisable to develop a national guideline for the study of drugs for AD treatment in accordance with the regulatory legal acts in force in the RF.

19 June 2024 in Regulatory Research and Medicine Evaluation
Verified
Journal Article
Open access
PDF file
ASA. P. Solovyova
A. P. Solovyova
ISI. M. Surmilo
I. M. Surmilo
INTRODUCTION. Generalised anxiety disorder (GAD) is the least studied anxiety disorder, as patients present with comorbid mood disorders. Finding effective treatment methods for GAD is of the utmost importance; therefore, it is essential to develop novel medicinal products for GAD. Proper clinical programme design is key to obtaining reliable data on the effectiveness and safety of a medicinal product. Currently, the Russian Federation lacks methodological guidelines for clinical studies of these medcinal products, and there is a need for developing such guidelines.AIM. This review aimed to assess the possibility of applying the methodological approaches described in international guidelines to Russian clinical trials to develop medicinal products for GAD.DISCUSSION. Having analysed the main provisions of the Guideline on the clinical investigation of medicinal products indicated for generalised anxiety disorder by the European Medicines Agency (EMA), the authors of this review outlined the main stages of clinical development and the methodology for using clinical data to evaluate the safety and efficacy of medicinal products for GAD. Clinical development programmes for these medicinal products should take into account research staging and mandatory long-term safety and additive effect assessments. This review highlights aspects of selecting the design, population, and primary and secondary endpoints for a clinical trial. Particular attention is paid to the consideration of comorbidities in patients.CONCLUSION. The provisions set forth in the EMA guideline can inform the development of national guidelines for studying medicinal products for GAD.

22 May 2024 in Patient-Oriented Medicine and Pharmacy
Verified
Journal Article
Open access
PDF file
VAV. V. Arkhipov
V. V. Arkhipov
DGD. V. Goryachev
D. V. Goryachev
ASA. P. Solovyova
A. P. Solovyova
This study aims to improve methodological approaches for conducting research in real-world practice. As an example of a real-world study, we present a comparative study of the use of botulinum toxin type A drugs as a part of medical technology for the treatment of spasticity syndrome in children with cerebral palsy. The methodological approaches proposed in this study can become the basis for organizing and conducting comparative clinical trials of drugs of the same pharmacotherapeutic group and contribute to the formation of framework criteria for real-world studies. The introduction of integrative methodological approaches to clinical trials in practice is designed to optimize pharmacotherapy and improve the efficiency of the healthcare system.

25 June 2020 in Russian Medicine
Verified
Journal Article
Open access
PDF file
VAVladimir V. Arkhipov
Vladimir V. Arkhipov
DGDmitry V. Goryachev
Dmitry V. Goryachev
NCNatalia V. Chebanenko
Natalia V. Chebanenko
ASAnna P. Solovyova
Anna P. Solovyova
ГВГорячев Дмитрий Владимирович
Горячев Дмитрий Владимирович
This paper presents a comprehensive assessment of safety monitoring of the use of botulinum toxin type A (BTA) drugs in the WHO databases (VigiBase) and automated information system (AIS) Roszdravnadzor-Pharmacovigilance, as well as a comparison of the dynamics of receipt of messages. The authors present a post-marketing study of domestic experience in the use of BTA drugs (Dysport, Botox, and Xeomin) based on a retrospective clinical and pharmacological analysis of 169 medical records of children with cerebral palsy in whom these drugs were used to treat spasticity syndrome. Analysis of the spectrum of adverse events, which were mentioned in 10 (5.9%) medical records, showed that their nature corresponded to the data set out in the instructions for medical use. Serious adverse reactions according to the criteria of severity death and threat to life, with a high degree of reliability of cause-and-effect relationship were not revealed during the study, which confirms a sufficiently high safety profile of these drugs. This paper focuses on improving the methodology for assessing the effectiveness and safety of BTA drugs for the treatment of spasticity syndrome in children and the need to identify and report all adverse drug reactions.